255 related articles for article (PubMed ID: 32461397)
1. Fibroscan as a non-invasive predictor of hepatic steatosis in women with polycystic ovary syndrome.
Chakraborty S; Ganie MA; Masoodi I; Jana M; ; Gupta N; Sofi NY
Indian J Med Res; 2020 Apr; 151(4):333-341. PubMed ID: 32461397
[TBL] [Abstract][Full Text] [Related]
2. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.
Polyzos SA; Goulis DG; Kountouras J; Mintziori G; Chatzis P; Papadakis E; Katsikis I; Panidis D
Hormones (Athens); 2014; 13(4):519-31. PubMed ID: 25402369
[TBL] [Abstract][Full Text] [Related]
3. Abdominal Obesity as a Predictive Factor of Nonalcoholic Fatty Liver Disease Assessed by Ultrasonography and Transient Elastography in Polycystic Ovary Syndrome and Healthy Women.
Tantanavipas S; Vallibhakara O; Sobhonslidsuk A; Phongkitkarun S; Vallibhakara SA; Promson K; Sophonsritsuk A
Biomed Res Int; 2019; 2019():9047324. PubMed ID: 31467918
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome: associated factors and noninvasive fibrosis staging in a single Brazilian center.
Taranto DOL; Guimarães TCM; Couto CA; Cândido AL; Azevedo RCS; Mattos FS; Elias MLC; Reis FM; Rocha ALL; Faria LC
Arch Endocrinol Metab; 2020; 64(3):235-242. PubMed ID: 32555989
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome.
Shengir M; Krishnamurthy S; Ghali P; Deschenes M; Wong P; Chen T; Sebastiani G
World J Gastroenterol; 2020 Nov; 26(44):7046-7060. PubMed ID: 33311949
[TBL] [Abstract][Full Text] [Related]
6. Controlled attenuation parameters to assess liver steatosis in obese patients with polycystic ovary syndrome.
Wang D; Nan N; Bing H; He B
Front Endocrinol (Lausanne); 2023; 14():1241734. PubMed ID: 37720537
[TBL] [Abstract][Full Text] [Related]
7. Polycystic Ovary Syndrome and Metabolic Syndrome: Clinical and Laboratory Findings and Non-Alcoholic Fatty Liver Disease Assessed by Elastography.
Lavor CBH; Viana Júnior AB; Medeiros FDC
Rev Bras Ginecol Obstet; 2022 Mar; 44(3):287-294. PubMed ID: 35576937
[TBL] [Abstract][Full Text] [Related]
8. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease in polycystic ovarian syndrome in Indian women.
Siwatch S; Singh V; Dhaliwal LK; Kumari S; Singh K
J Obstet Gynaecol; 2022 Jul; 42(5):957-961. PubMed ID: 34689689
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of Transient Elastography for Non-Invasive Diagnosis of Liver Fibrosis in Pediatric Non-Alcoholic Steatohepatitis.
Kwon YD; Ko KO; Lim JW; Cheon EJ; Song YH; Yoon JM
J Korean Med Sci; 2019 Jun; 34(23):e165. PubMed ID: 31197983
[TBL] [Abstract][Full Text] [Related]
11. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
Sagara M; Iijima T; Kase M; Kato K; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
J Diabetes Complications; 2021 May; 35(5):107885. PubMed ID: 33602617
[TBL] [Abstract][Full Text] [Related]
13. Polycystic ovary syndrome with feasible equivalence to overweight as a risk factor for non-alcoholic fatty liver disease development and severity in Mexican population.
Salva-Pastor N; López-Sánchez GN; Chávez-Tapia NC; Audifred-Salomón JR; Niebla-Cárdenas D; Topete-Estrada R; Pereznuñez-Zamora H; Vidaltamayo-Ramírez R; Báez-Arellano ME; Uribe M; Nuño-Lámbarri N
Ann Hepatol; 2020; 19(3):251-257. PubMed ID: 32111488
[TBL] [Abstract][Full Text] [Related]
14. Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome.
Vassilatou E; Lafoyianni S; Vassiliadi DA; Ioannidis D; Paschou SA; Mizamtsidi M; Panagou M; Vryonidou A
Maturitas; 2018 Oct; 116():1-7. PubMed ID: 30244768
[TBL] [Abstract][Full Text] [Related]
15. Relationship between nonalcoholic fatty liver disease and hyperandrogenemia in adolescents with polycystic ovary syndrome.
Kara O; Arsoy HA; Keskin M
Clin Exp Pediatr; 2023 Sep; 66(9):395-402. PubMed ID: 37321582
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome.
Romanowski MD; Parolin MB; Freitas AC; Piazza MJ; Basso J; Urbanetz AA
Arq Gastroenterol; 2015; 52(2):117-23. PubMed ID: 26039829
[TBL] [Abstract][Full Text] [Related]
17. Genetic Variants in nicotinamide-N-methyltransferase (NNMT) gene are related to the stage of non-alcoholic fatty liver disease diagnosed by controlled attenuation parameter (CAP)-fibroscan.
Hasan EM; Abd Al Aziz RA; Sabry D; Darweesh SK; Badary HA; Elsharkawy A; Abouelkhair MM; Yosry A
J Gastrointestin Liver Dis; 2018 Sep; 27(3):265-272. PubMed ID: 30240470
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic fatty liver disease is associated with hyperandrogenism in women with polycystic ovary syndrome.
Hong SH; Sung YA; Hong YS; Song DK; Jung H; Jeong K; Chung H; Lee H
Sci Rep; 2023 Aug; 13(1):13397. PubMed ID: 37591864
[TBL] [Abstract][Full Text] [Related]
19. MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY.
Paul J; Venugopal RV; Peter L; Shetty KNK; Shetti MP
Arq Gastroenterol; 2018; 55(1):7-13. PubMed ID: 29561981
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]